- An independent committee has recommended that Roche (RHHBY) end a Phase III trial of its MetMab (Onartuzumab) lung-cancer treatment, as the drug didn't show "clinically meaningful efficacy."
- The aim of the study was to assess whether Onartuzumab, when given with the oral therapy Tarceva, helped previously treated patients live longer compared with those who just received Tarceva.
- Analysts had viewed MetMab as a potential blockbuster and Roche is analyzing what the setback means for the drug's development.
- Shares are -1.7% in Zurich. (PR)